Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis (07/14/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report.
read more >
Biotech Boasts Compelling Pipeline
Source: Dr. Andre Uddin (06/23/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) is exploring financing options with some potential sources of capital, noted a Research Capital Corp. report.
read more >
Analyst Shares Thoughts After Microdisplay Co.'s Demo Day
Source: Jaeson Schmidt (06/23/2025)
Kopin Corp.'s (KOPN:NASDAQ) display and optical technologies as well as its products are impressive, noted a Lake Street Capital Markets report.
read more >
Interim Data From TID Trial Are Positive
Source: Streetwise Reports (05/15/2025)
Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.
read more >
One Co. With Cell Holding Device Stands Out in T1D Space
Source: Dr. Joseph Pantginis (04/28/2025)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) alone has shown favorable outcomes in a trial when patients with this disease were treated with an implanted device containing donor islets, noted an H.C. Wainwright & Co. report.
read more >